Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
- Resource Type
- Article
- Authors
- Kersting, Sabina ; Dubois, Julie; Nasserinejad, Kazem; Dobber, Johan A; Mellink, Clemens; van der Kevie-Kersemaekers, Anne-Marie F; Evers, Ludo M; de Boer, Fransien; Koene, Harry R; Schreurs, John; van der Klift, Marjolein; Velders, Gerjo A; van der Spek, Ellen; van der Straaten, Hanneke M; Hoogendoorn, Mels; van Gelder, Michel; Posthuma, Eduardus F M; Visser, Hein P J; Houtenbos, Ilse; Idink, Cecile A M; Issa, Djamila E; Dompeling, Ellen C; van Zaanen, Henk C T; Veelken, Hendrik; Levenga, Henriette; Tick, Lidwine W; Terpstra, Wim E; Tonino, Sanne H; Boyer, Michelle; Mobasher, Mehrdad; Levin, Mark-David ; Kater, Arnon P
- Source
- In The Lancet Haematology March 2022 9(3):e190-e199
- Subject
- Primary Research
Articles
- Language
- ISSN
- 2352-3026